Skip to content
1st Counsel – Lifestyle
Author:
Cenna Biosciences Inc.
Cenna Biosciences Receives FDA Clearance to Begin Phase 1a/1b Clinical Trial of 8M2D, a First-in-Class Peptide Designed to Stop the Production of Amyloid in Alzheimer’s Disease
June 17, 2026